Stock Events

BriaCell Therapeutics 

C$1.05
34
-C$0.03-2.78% Today

Statistics

Day High
1.05
Day Low
1.03
52W High
10.2
52W Low
0.84
Volume
1,605
Avg. Volume
12,754
Mkt Cap
20.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14JunConfirmed
Q3 2022
Q3 2022
Q4 2022
Q3 2023
Q3 2023
Q4 2023
Q1 2024
-1.02
-0.64
-0.27
0.11
Expected EPS
-0.55
Actual EPS
0.11

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BCT.TO. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is involved in developing cancer immunotherapies, directly competing with BriaCell's focus on advanced breast cancer treatments.
Merck &
MRK
Mkt Cap318.55B
Merck's strong presence in the oncology sector, especially with its blockbuster drug Keytruda, makes it a direct competitor in cancer treatment.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb has a robust lineup of cancer drugs and is actively involved in developing immunotherapies, competing in the same space as BriaCell.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, with its acquisition of Kite Pharma, has become a key player in the cancer immunotherapy market, competing with BriaCell's therapies.
Novartis
NVS
Mkt Cap232.42B
Novartis is a major pharmaceutical company with a strong emphasis on oncology, including breast cancer treatments, making it a competitor.
AMGEN
AMGN
Mkt Cap177.72B
Amgen's focus on innovative treatments for cancer places it in direct competition with BriaCell, especially in the development of biologics.
Roche
RHHBY
Mkt Cap220.72B
Roche, through its Genentech division, is a leader in cancer therapeutics, including breast cancer, competing with BriaCell's targeted approach.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca has a significant portfolio in oncology, including breast cancer treatments, making it a competitor in the same therapeutic area as BriaCell.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals' work in developing monoclonal antibodies for cancer treatment puts it in competition with BriaCell's immunotherapy approach.
Iovance Biotherapeutics
IOVA
Mkt Cap2.23B
Iovance Biotherapeutics focuses on T-cell-based therapies for cancer, competing in the innovative immunotherapy space alongside BriaCell.

About

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Show more...
CEO
Dr. William V. Williams M.D.
Employees
16
Country
CA
ISIN
CA1079301091
WKN
000A2PXS5

Listings

XNAS
US
BCTXW
TO
CA
BCT.TO
XNAS
US
BCTX
F
DE
8BT.F